Clinical Trial: Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab as a Third‐line or Later-line Therapy for Patients with Metastatic Gastric Cancer (China)

China, Aug. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab as a Third‐line or Later-line Therapy for Patients with Metastatic Gastric Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129977

Registration Time: 2026/08/12

Type: Interventional study

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=286726

Published by HT Digital Content Services with permission from Health Daily Digest....